從醫療用藥品到市售用藥品的轉換（切換OTC）市場 是由出版商Kalorama Information在2011年02月所出版的。
這份英文市場調查報告書包含280 Pages 價格從美金3500起跳。
回應了消費者對更便宜藥劑的需求，OTC藥的銷售量將增加。製造業者預測將會盡可能的將醫療用藥品轉換為市售用。今後對於高齡化等要因的切換OTC之動態將會加速。
本報告書為現在醫療用藥品到市售用藥品之轉換的市場動向、切換OTC成績與產品概要、將來的前景等，概述如下。
第1章 總綱
第2章 導論
第3章 過敏、咳嗽、感冒、膿瘻
- 概要
- 症狀概要
- 產品分析
- 預測將得到OTC認可的處方藥
- 市場分析
第4章 鎮痛劑以及其他止痛
第5章 抗炎症藥
第6章 胃腸藥
第7章 禁煙
第8章 其他藥劑分類
第9章 市場摘要
第10章 市場課題與動向
- 導論
- 法規體制當局
- 第3級
- 保險與贖回
- 對消費的影響
- 藥劑師的作用
- 對處方藥製造商的影響
- 產品擴大戰略
- 專利失效
- 標示的變更
- 國際的動向
第11章 企業簡介
Abstract
While many areas of the pharmaceutical industry will suffer from current
economic conditions worldwide, sales of over-the-counter drugs are widely
anticipated to grow as consumers seek cheaper alternatives. Manufacturers are
expected to switch prescription drugs to over-the-counter status where
possible. In the early part of the last decade there was a decline in
Rx-to-OTC switches; since 2006, however, there has been a number of uses of
this tactic to extend the revenue of pharmaceutical products. In Kalorama
Information' s Market for Rx to OTC Switches, we take a look at recent
switches, products that may switch in the future, and categories that can
benefit most from an OTC product.
The U.S. market for Rx-to-OTC switches encompasses a wide variety of products
that have been determined safe and effective as over-the-counter products. The
market is fueled by several factors including an aging population; steady to
increased incidences of conditions and diseases; new drug classes switched to
OTC; product demand; economic conditions and several other factors.
All product areas contribute to the growth and development of the OTC market;
however, new product development and additional regulatory review and approval
of new OTC drug classifications, specifically in areas such as
gastrointestinal drugs, cholesterol-reducing drugs, and contraceptives are
expected to make the most impact for continued growth.
As part of its coverage, this report includes:
- Current Market for Rx to OTC across major categories
- Past Results of OTC Switches
- Products Most Likely to Switch to OTC
- Assessment of the Economic Situation
The U.S. Market for Rx-to-OTC Switches focuses on several treatment segments
in which Rx-to-OTC switches are available:
- Allergy, Cough, Cold, and Sinus Products
- Analgesics, NSAIDs, and Pain Treatments
- Anti-Infectives
- Gastrointestinal Drugs
- Oral Care
- Smoking Cessation
- Other Drugs, including:
- Dental Rinses and Fluorides
- Hair Growth Products
- Rectal Ointments
- Sleep Aids
- Weight Management
- Hormone Replacement
In addition to the areas with switches in place, Kalorama Information has
identified other areas which may become open to Rx-to-OTC switches in the
future, including: cholesterol-reducing drugs, osteoporosis treatments,
overactive bladder and sexual dysfunction. The report covers OTC drugs that
were once only available by prescription due to either the active ingredient
or dosage of the drug.
Current and historical revenues for product segments include both the switched
brands and OTC drugs containing switched ingredients. Forecasted data includes
current products and forecasted switches which are outlined in the report.
The report includes statistical information for conditions and diseases
affecting the U.S. population, including detailed discussions, tables and
figures. Each segment provides an overview, descriptions of products on the
market, market estimates and forecasts, and competitive analysis of leading
providers. In addition to above-mentioned information, the report includes
current issues and trends affecting the industry and identifies trends that
may arise in the future.
Trends covered in the report include:
- Healthcare Flexible Spending Accounts and OTC Medicines
- A Third Class of Drug
- Insurance Issues and Reimbursement for OTC Drugs
- Health Insurance Trends in the United States
- Impact on the Consumer
- Online Resources for Health Information
- OTC Availability
- Health Expenditures
- Pharmacists Role
- Impact on the Prescription Drug Manufacturer
- Strategies for Continued Product Growth
- Mergers and Acquisitions
- Dual Status Switching
- Generic Competition
- Direct-to-Consumer Advertising
- Patent Expiration
- Labeling Changes
- International Trends in Rx-to-OTC Switches
- Consumers around the World
- Prescription vs Over-the-Counter Industry
- World Health, Demographics and Life Expectancy
- Life Expectancy
- Birth Rates
Companies profiled in this report include:
- Bayer Healthcare
- Boehringer Ingelheim
- GlaxoSmithKline
- Johnson & Johnson
- Merck/ Schering-Plough
- Novartis
- Pfizer/Wyeth
- Procter & Gamble
- Reckitt Benckiser
- Sanofi-Aventis/Chattem
The information for this report was gathered using both primary and secondary
research including comprehensive research of secondary sources such as company
literature, databases, investment reports, and medical and business journals.
Person-to-person, email and telephone interviews were the primary method of
gathering information. For the purpose of this study Kalorama Information
conducted interviews with approximately 50 industry officials, consultants,
health care providers, and government personnel. These sources were the
primary basis in gathering information specifically relating to revenue and
market share data presented in this report. Specific interviews with
pharmaceutical company representatives included marketing directors, division
managers, and product representatives.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting the Rx-to-OTC Switches Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- Overview of the Over-the-Counter Market
- Development of the Rx-to-OTC Drug Market
- Rx-to-OTC Industry
- Economic Indicators
- The FDA and Rx-to-OTC Switches
CHAPTER THREE: ALLERGY, COUGH, COLD, AND SINUS PRODUCTS
- Overview
- Antihistamines
- Decongestants
- Cough Preparations
- Mast Cell Stabilizer
- Ophthalmic Preparations
- Description of Conditions
- Allergic Rhinitis
- Common Cold
- Sinusitis
- Hives
- Ocular Allergies
- Product Analysis
- Switched Products
- Antihistamines
- Decongestants
- Cough Preparations
- Mast Cell Stabilizers
- Ophthalmic Preparations
- Prescription Products with Anticipated OTC Approvals
- Allegra
- Xyzal
- Clarinex
- Astelin Nasal Spray
- Flonase
- Nasacort AQ
- Rhinocort
- Nasonex
- Market Analysis
- Market Size and Forecast
- Competitive Analysis
CHAPTER FOUR: ANALGESICS AND OTHER PAIN RELIEVERS
- Overview
- Analgesics
- Nonsteroidal Anti-inflammatory Drugs
- Topical Pain Relievers and Other Similar Products
- Description of Conditions
- Product Analysis
- Switched Ingredients
- Antipruritic
- Internal analgesic/antipyretic
- Oral anesthetic
- Prescription Products with Anticipated OTC Approvals
- Nonsteroidal anti-inflammatory drugs
- Voltaren (diclofenac)
- Diflunisal
- Etodolac
- Nabumetone
- Feldene (piroxicam)
- Migraine treatments
- Imitrex
- Maxalt
- Zomig
- Other Migraine Treatments
- Market Analysis
- Market Size and Forecast
- Competitive Analysis
CHAPTER FIVE: ANTI-INFECTIVES
- Overview
- Antibiotics
- Antifungals
- Antivirals
- Antiparasitics
- Description of Conditions
- Vaginal Infections
- Athlete' s Foot
- Jock Itch
- Ringworm
- Dandruff
- Scabies and Pediculosis
- Pinworm
- Fungal Nail Infections
- Product Analysis
- Switched Ingredients
- Antifungals
- Anthelmintics
- Antimicrobials
- Pediculicides
- Prescription Products with Anticipated OTC Approvals
- Antivirals
- Zovirax
- Valtrex
- Denavir
- Influenza Antivirals
- Antibiotics
- Antifungals
- Market Analysis
- Market Size and Forecast
- Competitive Analysis
CHAPTER SIX: GASTROINTESTINAL DRUGS
- Overview
- Description of Conditions
- Nausea
- Diarrhea
- Constipation
- Heartburn
- Acid reflux
- Product Analysis
- Switched Ingredients
- Histamine H2 Inhibitors
- Proton Pump Inhibitors
- Antidiarrheals
- Laxatives
- Antiemetics
- Prescription Products with Anticipated OTC Approvals
- Proton Pump Inhibitors
- Nexium
- Protonix
- Aciphex
- Mucosal Protectants
- Antiemetics
- Market and Competitive Analysis
- Market Size and Fore
- Competitive Analysis
CHAPTER SEVEN: SMOKING CESSATION
- Overview
- Description of Conditions
- Lung Cancer and Tobacco Use
- Product Analysis
- Switched Ingredients
- Prescription Products with Anticipated OTC Approvals
- Market Analysis
- Market Size and Forecast
- Competitive Analysis
CHAPTER EIGHT: OTHER DRUG CLASSIFICATIONS
- Overview
- Contraceptives
- Dental Rinses and Fluorides
- Hair Growth Products
- Rectal Ointments
- Sleep Aids
- Weight Management
- Description of Conditions
- Pregnancy
- Global Birth Rates
- Abortion Rates
- Contraceptive Use
- Dental carries
- Hereditary Hair Loss
- Hemorrhoids
- Sleeplessness
- Obesity
- Conditions with Possible Future OTC Treatments
- Acne Vulgaris
- Elevated Cholesterol
- Osteoporosis
- Menopause and Hormone Replacement
- Erectile Dysfunction
- Urinary Incontinence/Overactive Bladder
- Benign Prostate Hypertrophy (BPH)
- Product Analysis
- Switched Ingredients
- Contraceptives
- Dental rinses and fluoride
- Hair growth
- Rectal ointments
- Sleep aids
- Weight Management
- Prescription Products with Anticipated OTC Approvals
- Acne Treatments
- Cholesterol-reducing Drugs (antilipidemics)
- Erectile Dysfunction
- Hair Loss Treatment
- Hormone-Replacement Therapies (HRT)
- Osteoporosis Treatments
- Overactive Bladder
- Sleep Aids
- Market Analysis
- Market Size and Forecast
- New Product Segments; Post 2015
- Antilipidemics
- Osteoporosis and Hormone Replacement
- Overactive Bladder
- Sexual Dysfunction
- Competitive Analysis
CHAPTER NINE: TOTAL MARKET SUMMARY
- Overview
- Total market Size and Forecast
- Competitive Analysis
- Market Analysis
CHAPTER TEN: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC MARKET
- Introduction
- Regulatory Authorities
- A Third Class of Drug
- Insurance Issues and Reimbursement for OTC Drugs
- Health Insurance Trends in the United States
- Healthcare Flexible Spending Accounts and OTC Medicines
- Impact on the Consumer
- Online Resources for Health Information
- OTC Availability
- Health Expenditures
- Pharmacists Role
- Impact on the Prescription Drug Manufacturer
- Strategies for Continued Product Growth
- Mergers and Acquisitions
- Sanofi-Aventis and Chattem Consumer
- Schering-Plough and Merck & Co.
- Wyeth and Pfizer
- Reckitt Benckiser and Adams Respiratory Therapeutics
- Bristol-Myers Squibb and Novartis AG
- Johnson & Johnson and Pfizer
- Reckitt Benckiser and Boots Healthcare
- Bayer and Roche
- Dual Status Switching
- Generic Competition
- Direct-to-Consumer Advertising
- Patent Expiration
- Labeling Changes
- International Trends in Rx-to-OTC Switches
- Consumers around the World
- Prescription vs Over-the-Counter Industry
- World Health, Demographics and Life Expectancy
- Life Expectancy
- Birth Rates
CHAPTER ELEVEN: COMPANY PROFILES
- Introduction
- Bayer Healthcare
- Boehringer Ingelheim
- GlaxoSmithKline
- Johnson & Johnson
- Merck/ Schering-Plough
- Novartis
- Pfizer/Wyeth
- Procter & Gamble
- Reckitt Benckiser
- Sanofi-Aventis/Chattem
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
EXECUTIVE SUMMARY
- Table 1-1 The U.S. Market for Rx-to-OTC Switches 2005-2015 Compound Annual
Growth Rate
- Figure 1-1 The U.S. Market for Rx-to-OTC Switches, 2005-2015
INTRODUCTION
- Table 2-1 OTC Retail Sales, 1976-2009
- Figure 2-1 OTC Retail Sales, 1976-2009
- Table 2-2 Rx-to-OTC Switches Approved by the FDA 1976-2010
- Figure 2-2 Number of New Rx-to-OTC Switches by the FDA per Year 1976-2010
- Table 2-3 Statistics for Selected Rx-to-OTC Switches (United States)
- Table 2-4 Estimated OTC Sales by Product Type and Percent of Sales
Attributed to Rx-to-OTC Switched Ingredients
- Figure 2-3 Estimated OTC Sales by Product Type and Percent of Sales
Attributed to Rx-to-OTC Switched Ingredients
- Table 2-5 U.S. Population by Sex, 2005-2050
- Figure 2-4 U.S. Population by Sex, 2005-2050
- Table 2-6 United States Population Trend Age 65+
- Figure 2-5 United States Population Trend Age 65+
- Table 2-7 World Population by Sex, 2005-2050
- Figure 2-6 World Population by Sex, 2005-2050
- Table 2-8 World Population Trend Age 65+
- Figure 2-7 World Population Trend Age 65+
- Table 2-9 Healthcare Industry Inflation Rates Healthcare Industry Consumer
Price Index Comparisons Based on 2009 Data
- Figure 2-8 Healthcare Industry Inflation Rates Healthcare Industry
Consumer Price Index Comparisons Based on 2009 Data
- Table 2-10 FDA Human Drugs Outcomes Table, FY 2005 - FY 2009
ALLERGY, COUGH, COLD, AND SINUS PRODUCTS
- Table 3-1 Incidence of Allergy, Cough, Cold, Sinus Conditions 2010
- Figure 3-1 World Incidence of Allergy, Cough, Cold, Sinus Conditions,
Superimposed on Total Population, 2010
- Table 3-2 Allergy, Cough, Cold, Sinus Product Ingredients Transferred from
Rx-to-OTC Status
- Table 3-2 (continued) Allergy, Cough, Cold, Sinus Product Ingredients
Transferred from Rx-to-OTC Status
- Figure 3-2 Allergy, Cough, Cold, Sinus Product Ingredients Transferred
from Rx-to-OTC by Year
- Table 3-3 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 3-4 The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold, and
Sinus Product Revenues 2005-2015 Compound Annual Growth Rate
- Figure 3-3 The U.S. Market for Rx-to-OTC Switches Allergy, Cough, Cold,
and Sinus Product Revenues 2005-2015
- Figure 3-4 The U.S. Market for Rx-to-OTC Switches: Allergy, Cough, Cold,
and Sinus Products, by Percent and Product Type, 2010
- Table 3-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches: Allergy, Cough, Cold, and Sinus Products, 2010
- Figure 3-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches: Allergy, Cough, Cold, and Sinus Products, 2010
ANALGESICS AND OTHER PAIN RELIEVERS
- Table 4-1 Incidence of Conditions with Pain and Inflammatory Symptoms 2010
- Figure 4-1 World Incidence of Conditions with Pain and Inflammatory
Symptoms Superimposed on Total Population, 2010
- Table 4-2 Analgesics, NSAIDs and Other Ingredients Transferred from
Rx-to-OTC Status
- Figure 4-2 Analgesics, NSAIDs and Other Ingredients Transferred from
Rx-to-OTC by Year
- Table 4-3 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 4-4 The U.S. Market for Rx-to-OTC Switches Analgesic Product
Revenues 2005-2015 Compound Annual Growth Rate
- Figure 4-3 The U.S. Market for Rx-to-OTC Switches Analgesic Product
Revenues 2005-2015
- Figure 4-4 The U.S. Market for Rx-to-OTC Switches: Analgesic Product Type,
2010
- Table 4-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Analgesics 2010
- Figure 4-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Analgesics 2010
ANTI-INFECTIVES
- Table 5-1 Incidence of Infections by Type, 2010
- Figure 5-1 Incidence of Infections by Type, 2010
- Table 5-2 Anti-infectives Ingredients Transferred from Rx-to-OTC Status
- Figure 5-2 Anti-infectives Ingredients Transferred from Rx-to-OTC by Year
- Table 5-3 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 5-4 The U.S. Market for Rx-to-OTC Switches Anti-infective Product
Revenues 2005-2015 Compound Annual Growth Rate
- Figure 5-3 The U.S. Market for Rx-to-OTC Switches Anti-infective Product
Revenues 2005-2015
- Figure 5-4 The U.S. Market for Rx-to-OTC Switches: Anti-infective Product
Type, 2010
- Table 5-5 Leading Suppliers' Shares of The U.S. Market for Rx-to-OTC
Switched Anti-infectives 2010
- Figure 5-5 Leading Suppliers' Shares of The U.S. Market for Rx-to-OTC
Switched Anti-infectives 2010
CHAPTER SIX: GASTROINTESTINAL DRUGS
- Table 6-1 Incidence of Gastrointestinal Conditions, 2010
- Figure 6-1 Incidence of Gastrointestinal Conditions, 2010
- Table 6-2 Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC
Status
- Figure 6-2 Gastrointestinal Drug Ingredients Transferred from Rx-to-OTC by
Year
- Table 6-3 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 6-4 The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug
Revenues 2005-2015 Compound Annual Growth Rate
- Figure 6-3 The U.S. Market for Rx-to-OTC Switches Gastrointestinal Drug
Revenues 2005-2015
- Figure 6-4 The U.S. Market for Rx-to-OTC Switches: Gastrointestinal Drug
by Product Type, 2010
- Table 6-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Gastrointestinal Drugs 2010
- Figure 6-5 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Gastrointestinal Drugs 2010
SMOKING CESSATION
- Table 7-1 Percent of Smokers by Country
- Figure 7-1 Average Percent of Smokers Worldwide in Developed Regions
- Table 7-2 Estimated World Incidence of Lung Cancer by Country, 2010
- Figure 7-2 Estimated World Incidence of Lung Cancer by Country, 2010
- Table 7-3 Smoking Cessation Product Ingredients Transferred from Rx-to-OTC
Status
- Figure 7-3 Smoking Cessation Product Ingredients Transferred from
Rx-to-OTC Status
- Table 7-4 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 7-5 The U.S. Market for Rx-to-OTC Switches Smoking Cessation Product
Revenues 2005-2015 Compound Annual Growth Rate
- Figure 7-4 The U.S. Market for Rx-to-OTC Switches Smoking Cessation
Product Revenues 2005-2015
- Figure 7-5 The U.S. Market for Rx-to-OTC Switches: Smoking Cessation
Product Type, 2010
- Table 7-6 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Smoking Cessation Drugs 2010
- Figure 7-6 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Smoking Cessation Drugs 2010
OTHER DRUG CLASSIFICATIONS
- Table 8-1 Crude Birth Rate per 1,000 Persons 2000, 2005 and Estimated 2010
- Figure 8-1 Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected 2010
- Table 8-2 Number of Abortions in the United States by Year, 1990-2005
- Figure 8-2 Number of Abortions in the United States by Year, 1990-2005
- Table 8-3 Estimated U.S. Contraceptive Use by Method, 2006-2008
- Table 8-4 Percentage of U.S. Incidence of Untreated Dental Carries by Age
Group
- Table 8-5 Alopecia Trends by World Region
- Table 8-6 Percent of Obese* Population, 2006
- Table 8-7 Miscellaneous Drug Ingredients Transferred from Rx-to-OTC Status
by Trade Name, Distributor, and Date of OTC Approval
- Figure 8-3 Miscellaneous Drug Ingredients Transferred from Rx-to-OTC by
Year
- Table 8-8 Prescription Drugs with Anticipated OTC Approval by Ingredient,
Trade Name, Distributor and Current Activity
- Table 8-8 (continued) Prescription Drugs with Anticipated OTC Approval by
Ingredient, Trade Name, Distributor and Current Activity
- Table 8-9 The U.S. Market for Rx-to-OTC Switches Other Drug Classification
Product Revenues 2005-2015 Compound Annual Growth Rate
- Figure 8-4 The U.S. Market for Rx-to-OTC Switches Other Drug
Classification Product Revenues 2005-2015
- Table 8-10 The U.S. Market for Rx-to-OTC Switches Other Drug
Classifications Revenues by Product Type 2005-2015 Compound Annual Growth Rate
- Figure 8-5 The U.S. Market for Rx-to-OTC Switches Other Drug
Classifications Revenues by Product Type 2005-2015
- Figure 8-6 The U.S. Market for Rx-to-OTC Switches Other Drug
Classifications Distribution of Revenues by Product Type 2010
- Table 8-11 Leading Suppliers' Shares of the U.S. Market for Rx-to-OTC
Switches Other Drug Classifications 2010
- Figure 8-7 Leading Suppliers' Shares of the U.S. Market for Rx-o-OTC
Switches Other Drug Classifications 2010
TOTAL MARKET SUMMARY
- Table 9-1 The U.S. Market for Rx-to-OTC Switches 2005-2015 Compound Annual
Growth Rate
- Figure 9-1 The U.S. Market for Rx-to-OTC Switches, 2005-2015 Markets by
Segments
- Figure 9-2 The U.S. Market for Rx-to-OTC Switches by Product Category,
2005-2015
- Figure 9-3 The U.S. Market for Rx-to-OTC Switches, Distribution of
Revenues by Product Category 2010
- Table 9-2 Leading Suppliers Significant Segments of Participation within
the U.S. Market for Rx-to-OTC Switches, 2010
- Figure 9- Leading Suppliers Market Share in the U.S. Market for Rx-to-OTC
Switches, 2010
ISSUES AND TRENDS AFFECTING THE RX-TO-OTC MARKET
- Table 10-1 Health Insurance Trends in the United States 2003-2007
- Table 10-2 National Healthcare Expenditures in the United States 1960-2015
- Figure 10-1 Healthcare Expenditures in the United States
- Figure 10-2 Healthcare Spending as a Percent of GDP in the United States
- Figure 10-3 Internet Users per 100 Inhabitants, 2010
- Table 10-3 Number of Retail Establishments in the United States and
Non-Prescription Medicine Sales, 2007
- Table 10-4 Total Healthcare Expenditures as a Percent of GDP by Country
1990, 2000 and 2006
- Figure 10-4 Total Healthcare Expenditures as a Percent of GDP by Country
1990, 2000, and 2006
- Table 10-5 Average Annual Expenditures per Consumer Unit for Healthcare
2005-2007
- Figure 10-5 Typical Pharmacist-Consumer OTC Drug Counseling Session
- Table 10-6 U.S. Patent Expirations for Select Prescription Pharmaceuticals
- Table 10-7 Legal Classification Status of Selected Ingredients Worldwide
- Table 10-7 Legal Classification Status of Selected Ingredients Worldwide
(continued)
- Table 10-7 Legal Classification Status of Selected Ingredients Worldwide
(continued)
- Table 10-8 Individual Ingredients Switched from Rx to OTC by Country,
2009/2010
- Table 10-8 (continued) Individual Ingredients Switched from Rx to OTC by
Country, 2009/2010
- Table 10-9 Total Pharmaceutical Markets, Prescription vs. Non-Prescription
by Country, 2009
- Figure 10-7 Total Pharmaceutical Markets, Prescription vs.
Non-Prescription by Country, 2009
- Table 10-10 Average Life Expectancy in Years by Country 1980, 2004 and 2009
- Table 10-11 Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected
2010
- Figure 10-8 Crude Birth Rate per 1,000 Persons 2000, 2005 and Projected
2010
COMPANY PROFILES
|
